Publications by authors named "Walburga Engel-Riedel"

Claim this Profile
R
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).
Farastuk Bozorgmehr, Inn Chung, Jürgen R Fischer, Marc Bischof, Akin Atmaca, Walburga Engel-Riedel

Clin Exp Metastasis· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evolutionary trajectories of small cell lung cancer under therapy.
Julie George, Lukas Maas, Nima Abedpour, Maria Cartolano, Laura Kaiser, Walburga Engel-Riedel

Nature· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial.
Gerhard Held, Lorenz Thurner, Viola Poeschel, German Ott, Christian Schmidt, Walburga Engel-Riedel

Hemasphere· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer.
Sebastian Michels, Carina Heydt, Bianca van Veggel, Barbara Deschler-Baier, Nuria Pardo, Walburga Engel-Riedel

JCO Precis Oncol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming EGFR-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.
Jana Fassunke, Fabienne Müller, Marina Keul, Sebastian Michels, Marcel A Dammert, Walburga Engel-Riedel

Nat Commun· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance.
Petros Christopoulos, Marc A Schneider, Farastuk Bozorgmehr, Jonas Kuon, Walburga Engel-Riedel

Lung Cancer· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, controlled trial evaluating the efficacy and safety of BTH1677 in combination with bevacizumab, carboplatin, and paclitaxel in first-line treatment of advanced non-small cell lung cancer.
Walburga Engel-Riedel, Jamie Lowe, Paulette Mattson, J Richard Trout, Richard D Huhn

J Immunother Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
6
65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer.
Wolfgang Schuette, Claus-Peter Schneider, Walburga Engel-Riedel, Christian Schumann, Martin Kohlhaeufl

Lung Cancer (Auckl)· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Trimodal Therapy for Stage IIIA-B NSCLC Involving High Dose Neoadjuvant Chemoradiotherapy. Is Surgery a Rational Option?].
Aris Koryllos, Corinna Ludwig, Walburga Engel-Riedel, Michaela Hammer-Helmig, Erich Stoelben

Zentralbl Chir· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The (Con-) Fusion in ALK Diagnostics: When Food and Drug Administration-Approved Algorithms Fail.
Jessica Jürgens, Walburga Engel-Riedel, Erich Stoelben, Verena Schildgen, Oliver Schildgen

J Clin Oncol· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
GILT--A randomised phase III study of oral vinorelbine and cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral vinorelbine and cisplatin or best supportive care alone in stage III non-small cell lung cancer.
Michael Flentje, Rudolf M Huber, Walburga Engel-Riedel, Stefan Andreas, Jens Kollmeier

Strahlenther Onkol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).
Michael Kreuter, Johan Vansteenkiste, Jürgen R Fischer, Wilfried E Eberhardt, Heike Zabeck, Walburga Engel-Riedel

J Thorac Oncol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients.
Sebastian Michels, Andreas Hans Scheel, Matthias Scheffler, Anne Maria Schultheis, Oliver Gautschi, Walburga Engel-Riedel

J Thorac Oncol· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular Pathology and Personalized Medicine: The Dawn of a New Era in Companion Diagnostics-Practical Considerations about Companion Diagnostics for Non-Small-Cell-Lung-Cancer.
Till Plönes, Walburga Engel-Riedel, Erich Stoelben, Christina Limmroth, Oliver Schildgen

J Pers Med· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.
Gerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, Wolfgang Schuette, Jan Stöhlmacher

Lung Cancer· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Pilar Garrido, Walburga Engel-Riedel, Monika Serke, Philippe Giraud, Umberto Ricardi

Lung Cancer· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung.
Hans-Ulrich Schildhaus, Anne M Schultheis, Josef Rüschoff, Elke Binot, Sabine Merkelbach-Bruse, Walburga Engel-Riedel

Clin Cancer Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Matthias Scheffler, Marc Bos, Masyar Gardizi, Katharina König, Sebastian Michels, Walburga Engel-Riedel

Oncotarget· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absence of amplification of the FGFR1-gene in human malignant mesothelioma of the pleura: a pilot study.
Till Plönes, Frank Beckers, Walburga Engel-Riedel, Erich Stoelben, Michael Brockmann

BMC Res Notes· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients.
Jessica Jürgens, Walburga Engel-Riedel, Alexander Prickartz, Corinna Ludwig, Oliver Schildgen

Future Oncol· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic impact of [18F]fluorothymidine and [18F]fluoro-D-glucose baseline uptakes in patients with lung cancer treated first-line with erlotinib.
Matthias Scheffler, Thomas Zander, Lucia Nogova, Carsten Kobe, Deniz Kahraman, Walburga Engel-Riedel

PLoS One· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
Verena Schildgen, Jessica Lüsebrink, Jan D Appel, Christine Wübben, Walburga Engel-Riedel

Diagn Mol Pathol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination of Pyrosequencing and Sanger sequencing reveals alleged novel mutation in exon 18 of EGFR.
Verena Schildgen, Carolin Schulz, Jessica Lüsebrink, Ramona-Liza Tillmann, Walburga Engel-Riedel

Per Med· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer.
Martin Peifer, Lynnette Fernández-Cuesta, Martin L Sos, Julie George, Danila Seidel, Walburga Engel-Riedel

Nat Genet· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing.
Marcin Imielinski, Alice H Berger, Peter S Hammerman, Bryan Hernandez, Trevor J Pugh, Walburga Engel-Riedel

Cell· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis